Infliximab treatment for resistant Achilles tendonitis.

Abstract	Undifferentiated spondyloarthropathies USPA can sometimes be refractory to usual disease modifying agents. Anti-tumor necrosis factor TNF-alpha agents have been shown to be effective in spondyloarthropathies. Few articles described the efficacy of TNF-alpha antagonists in USPA. Our patient had refractory Achilles tendonitis as an early manifestation of USPA which responded dramatically to infliximab treatment.
Authors	Said M Al-Asfar, Mohammad Attar, Hasan Shacfeh
Journal	Saudi medical journal (Saudi Med J) Vol. 30 Issue 9 Pg. 1228-30 (Sep 2009) ISSN: 0379-5284 [Print] Saudi Arabia
PMID	19750273 (Publication Type: Case Reports, Journal Article)
Chemical References	Anti-Inflammatory Agents Antibodies, Monoclonal Tumor Necrosis Factor-alpha Infliximab
Topics	Achilles Tendon (pathology) Adult Animals Anti-Inflammatory Agents (pharmacology, therapeutic use) Antibodies, Monoclonal (pharmacology, therapeutic use) Humans Infliximab Magnetic Resonance Imaging Male Tendinopathy (diagnosis, drug therapy) Tumor Necrosis Factor-alpha (antagonists & inhibitors)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!